Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival: Tumor Thrombus Consistency and Survival by Mager, Rene et al.
Renal cell carcinoma with Inferior vena cava involvement: 
Prognostic effect of Tumor thrombus consistency on cancer 
specific survival
Rene Mager, M.D.1, Siamak Daneshmand, M.D.2, Christopher P. Evans, M.D.3, Joan Palou, 
M.D., Ph.D.4, Juan I. Martínez-Salamanca, M.D.5, Viraj A. Master, M.D., Ph.D.6, James M. 
McKiernan, M.D.7, John A. Libertino, M.D.8, and Axel Haferkamp, M.D.1,* On behalf of the 
International Renal Cell Carcinoma-Venous Thrombus Consortium
1Department of Urology and Pediatric Urology, University Medical Center Mainz, 
Langenbeckstraβe 1, 55131, Mainz, Germany
2USC/Norris Comprehensive Cancer Center, 1441 Eastlake Ave # 7416, Los Angeles, California 
90089, USA
3Department of Urology, UC Davis Medical Center, 4860 Y St., Suite 2200 | Sacramento, 
California 95817, USA
4Department of Urology, Fundació Puigvert, Carrer de Cartagena 340-350, 08025 Barcelona, 
Spain
5Department of Urology, Hospital Universitario Puerta de Hierro-Majadahonda, Calle Manuel de 
Falla, 1, 28222 Majadahonda, Madrid, Spain
6Department of Urology, Emory University, 1365 Clifton Rd Bldg-B, 30322 Atlanta, Georgia, USA
7Department of Urology, Columbia University College of Physicians and Surgeons, 630 West 
168th Street, New York, New York 10032, USA
8Department of Urology, Lahey Clinic, 41 Burlington Mall Road, Burlington, Massachusetts 
01805, USA
Abstract
Background—Renal cell carcinoma forming a venous tumor thrombus (VTT) in the inferior 
vena cava (IVC) has a poor prognosis. Recent investigations have been focused on prognostic 
markers of survival. Thrombus consistency (TC) has been proposed to be of significant value but 
yet there are conflicting data. The aim of this study is to test the effect of IVC VTT consistency on 
cancer specific survival (CSS) in a multi-institutional cohort.
Methods—The records of 413 patients collected by the International Renal Cell Carcinoma-
Venous Thrombus Consortium were retrospectively analyzed. All patients underwent radical 
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nephrectomy and tumor thrombectomy. Kaplan-Meier estimates and Cox regression analyses 
investigated the impact of TC on CSS in addition to established clinicopathological predictors.
Results—VTT was solid in 225 patients and friable in 188 patients. Median CSS was 50 months 
in solid and 45 months in friable VTT. TC showed no significant association with metastatic 
spread, pT stage, perinephric fat invasion and higher Fuhrman grade. Survival analysis and Cox 
regression rejected thrombus consistency as prognostic marker for CSS.
Conclusions—In the largest cohort published so far, TC seems not to be independently 
associated with survival in RCC patients and should therefore not be included in risk stratification 
models.
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Introduction
Renal cell carcinoma (RCC) represents roughly 3% of cancers worldwide [1] and its 
estimated incidence is approximately 12/100000 in the US and Europe [2,3]. In 4-10% of 
patients RCC forms a venous tumor thrombus (VTT) and invades the inferior vena cava [4] 
(IVC). VTT is considered to be an independent adverse prognostic parameter [5]. Although 
approximately 44% of patients with RCC and VTT present with synchronous metastases 
resulting in a reduced 5-year CSS between 17% and 36% surgery remains the first treatment 
option [6]. In those cases nephrectomy plus thrombectomy may result in improved survival 
and better effect of subsequent targeted therapy [7,8]. Recently, tumor thrombus consistency 
gained attention for its prognostic value:
In a retrospective study cohort of 174 patients, friable thrombus consistency was an 
independent predictor of survival and was associated with a significantly poorer CSS and 
overall survival (OS) [9].
At present two studies have been published trying to validate these results: A retrospective 
analysis of 200 patients confirmed significantly shorter OS for patients with friable 
thrombus consistency but failed to demonstrate significance of thrombus consistency in 
predicting survival independently. Solely in the subgroup of non-metastasized patients 
thrombus consistency was of predictive value [10].
Conversely, in another cohort of 147 patients thrombus consistency was not related to 
survival [11].
Given these apparent controversies, we aimed to evaluate the prognostic effect of tumor 
thrombus consistency in patients with IVC involvement in the largest multi-institutional 
cohort of IVC patients available.
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The patients of our study were collected retrospectively by the International Renal Cell 
Carcinoma-Venous Thrombus Consortium (IRCCVTC). Prior to data collection all of the 
participating centers provided local ethics committee approval for their site. Data were 
submitted according to the IRCCVTC criteria and were cleared for data inconsistencies 
[12,13]. We retrospectively enrolled 477 patients who underwent radical nephrectomy and 
IVC tumor thrombectomy of hard or elastic VTT from 1975 to 2014 in 16 European und US 
centers. Patient records incomplete for tumor thrombus level, TNM staging, Fuhrman grade 
and perinephric fat invasion were excluded from analysis.
Definition of variables
Thrombus consistency was classified binarily as friable or solid depending on the surgeon's 
intraoperative discovery of pliable and slithery or hard and barely compressible thrombotic 
tissue.
Thrombus level was defined according to Mayo classification [14]. Only inferior vena cava 
tumor thrombus patients (level I-IV) were part of the study. TNM staging corresponded to 
the 2009 system [15]. Renal cell carcinomas were of clear cell, papillary or chromophobe 
histological subtype [16]. Other renal neoplasms were excluded from study cohort [17]. 
Type 1 and 2 papillary RCC were not distinguished.
Follow up
Follow-up was conducted according to local standards. Date of last follow-up and date of 
death was available for survival analysis. Cause of death was specified to distinguish cancer 
specific from cancer independent death.
Statistical analysis
The distribution of IVC tumor thrombus consistency in categorical clinicopathological 
variables was assessed using Chi square test or Fisher's exact test. Continuous variables were 
analyzed by T test. Survival was calculated from the date of surgery to last follow-up or 
death. Tumor-independent death was censored. Survival analysis was performed with 
Kaplan-Meier estimates and variables were compared using log rank test according to Peto-
Pike. The clinicopathologic variables thrombus consistency, thrombus level, pT stage, 
presence of metastasis, Fuhrman grade and perinephric fat invasion were selected for 
evaluation of their prognostic significance on cancer specific survival. To assess the 
variable's impact on survival univariable and multivariable analysis were performed using 
Cox proportional hazard regression model. All tests were two-sided and a p value of p<0.05 
was considered significant. Data were analyzed using Bias software (epsilon, Frankfurt, 
Germany) [18].
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Of 477 patients enrolled, 413 patients fulfilled all aforementioned criteria and were available 
for analysis. There were 225 patients (54%) with solid and 188 patients (46%) with friable 
tumor thrombus in the inferior vena cava. Clinical and pathological features separated for 
solid and friable tumor thrombus consistency are shown in Table 1. Neither friable nor solid 
tumor thrombus showed significant association with the histological subtype, presence of 
nodal or distant metastases, pT stage, and higher Fuhrman grade, IVC wall invasion or 
perinephric fat invasion. The median cancer specific survival of the whole study cohort was 
50 months (range 0 -328 months). Over the analyzed period of 32 years cancer specific 
death occurred in 172 patients (42%). 5-year cancer specific survival probability was 47.6%. 
Kaplan-Meier curves of cancer specific survival in patients with friable and solid caval 
tumor thrombus are presented in Figure 1. Clinicopathologic variables and their influence on 
survival are shown in Table 2. Log rank test revealed no significant difference in cancer 
specific survival between patients with friable or solid IVC tumor thrombus. There were 
significant differences in survival rates between patients with and without a positive nodal 
status, distant metastasis, perinephric fat invasion and IVC wall invasion. Metastatic disease 
had a poor 5-year CSS of 26% significantly different from non-metastatic disease with 62% 
[HR = 3.1, CI: (2.4, 4.2), log rank test]. In univariable Cox regression analysis thrombus 
consistency failed to be of significance in prediction of cancer specific survival, whereas all 
other selected variables pretended to be of predictive value (Table 3). Multivariable Cox 
regression analysis confirmed thrombus level, nodal status and distant metastases as 
predictive variables for cancer specific survival. Similar results were shown in sub analyses, 
limited to non-metastatic and metastatic. Furthermore the latest subgroup of patients 
operated between 2006 and 2014 were analyzed the same way and demonstrated similar 
results (data not shown).
Discussion
Locally advanced renal cell carcinoma with venous tumor thrombus is a grave disease with 
an unfavorable prognosis. Even if staging at diagnosis reveals no sign of metastases in our 
N0M0 subgroup it is accompanied with cancer specific death in approximately 29% of 
cases. Surgical resection remains the only treatment option for cure in non-metastatic 
disease and is also part of a multimodal treatment approach in metastatic disease because 
targeted therapy alone is considered to be less effective [7,8,19-21]. However in most 
patients with IVC involvement of RCC survival is limited. Taken into account the high risk 
of tumor recurrence or progression in patients with RCC and IVC despite surgery prognostic 
markers to identify patients in need for further treatment or closer follow up would be 
beneficial. In view of recently published data [9-11] the current study aimed to validate if 
thrombus consistency could serve as a significant and relevant prognostic marker for 
survival. Interestingly in our large multi-institutional cohort of 413 patients thrombus 
consistency neither is significantly involved in cancer specific survival analyzing Kaplan-
Meier curves nor contributes significantly to survival in univariable and multivariable Cox 
regression. Dividing the study population into metastasized and non-metastasized patients 
demonstrated the same results for each subgroup.
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Our results support recently published data by Antonelli et al. where tumor consistency also 
failed to serve as a predictive marker for survival in a smaller cohort of 147 patients [11]. 
These observations are in contrast to Bertini et al. who were able to show a significantly 
decreased cancer specific survival in patients with friable tumor thrombus in their study 
cohort of 174 patients with renal vein or IVC tumor thrombus. This unfavourable prognostic 
parameter was significant for their whole study cohort and for the non-metastasized 
subgroup.
The different prognostic relevance of tumor thrombus consistency between our data and 
Bertini et al. might result from inhomogeneous distribution of clinicopathologic features and 
from inclusion of level 0 VTT (renal vein tumor thrombus only). In the data set of Bertini et 
al. the friable thrombus consistency group was significantly associated with aggressive 
tumor characteristics such as nodal metastases, distant metastases or perinephric fat invasion 
whereas solid VTT was significantly associated with level 0 VTT which is known to be of 
significantly improved outcome compared to level I or higher VTT [21,22]. In our cohort of 
level I-IV VTT there was homogeneous distribution of these characteristics between friable 
and solid thrombus consistency group. Metastatic disease has been proven to be the 
strongest predictive factor for survival [7,9-11,22,23] and perinephric fat invasion has been 
considered to be an independent adverse prognostic marker in metastasized patients [11]. 
Our results support the hypothesis that poor outcome in patients with friable thrombus 
consistency as reported by Bertini et al. might rather be biased by the dominating impact of 
these unfavorable tumor characteristics than caused by friable thrombus related lack of cell 
adhesion molecules [10,11].
The other previously published study by Weiss et al. with 200 patients reported that friable 
thrombus consistency was solely significant in multivariable analysis of OS in non-
metastasized patients [10]. These results might indicate again the dominating impact of 
metastatic disease on survival. Furthermore the inclusion of 137 level 0 VTT patients 
associated with solid thrombus consistency in 70% might bias the favorable survival in the 
solid thrombus consistency group [10].
In accordance to previously published data our study confirmed the impact of different 
clinicopathologic variables on survival: Thrombus level I and II showed a significantly 
increased survival compared to level III and IV and multivariable analysis confirmed 
thrombus level as independent prognostic marker in non-metastasized patients [7,13,24,25]. 
As reported by Bertini et al. and Weiss et al. predictive value of pT stage was restricted to 
univariable analysis [9,10]. In multivariable analysis redundancy of the variables thrombus 
level and perinephric fat invasion in pT stage analysis might bias the results. In non-
metastasized tumor patients Fuhrman grade and thrombus level were independent predictors 
of poor survival indicating the tumor's capacity to invasive growth or metastatic spread [7]. 
IVC wall invasion deteriorated CSS significantly as previously reported by Hatcher et al. but 
was no independent predictor for survival in multivariable analysis [26].
In summary metastatic spread such as nodal involvement or distant metastases is the most 
decisive variable for survival exceeding almost all variables of locally advanced RCC: In the 
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current study population, once metastasized, 5-year CSS probability is reduced by 60% 
compared to the non-metastasized group.
To complete the analysis of the impact of venous tumor thrombus consistency on RCC 
patients we further investigated how thrombus consistency would influence the surgical 
technique: Multivariable analysis revealed that thrombus consistency was no independent 
predictor for the necessity of cavectomy, cavotomy or Pringle maneuver whereas thrombus 
level - as commonly recognized [27,28] - proved to be of significant predictive value (data 
not shown).
Our study had several limitations determined by retrospective analysis and multi-
institutional approach. IRCCVTC databank included 477 patients but due to missing data 
and non-RCC histopathology only 413 patients met all criteria mandatory for multivariable 
analysis. In contrast to previous publications where thrombus consistency was classified by 
histopathological re-evaluation [9-11], IRCCVTC data was limited to surgeons' 
intraoperative description of thrombus consistency. This might be negligible since Bertini 
has provided statistical measure of interrater-agreement between surgeons' description and 
retrospective histopathologic re-evaluation in a subgroup of 61 patients showing an excellent 
agreement (κ = 0.83) equal to the interrater-agreement between two pathologists (κ = 0.78) 
[9]. Our results might be biased by innovations in diagnostics, surgical treatment and 
targeted therapy during the analyzed period. Treatment of mRCC has changed dramatically 
with approval of targeted therapy in 2006. In our cohort 201 (49%) of patients had their date 
of surgery between 2006 and 2014 when targeted therapy was available. Of these 104 
patients had solid and 97 had friable VTT. To exclude targeted therapy to have a relevant 
impact we performed additional analysis of this subgroup demonstrating similar results. 
Therefore we assume equal influence of targeted therapy on CSS in the friable VTT and 
solid VTT subgroup. Despite these limitations, to our knowledge, this study provides the 
largest number of patients with RCC and VTT with IVC involvement analyzed for the 
impact of thrombus consistency on survival so far.
Conclusions
Our large multi-institutional and international study cohort provided unique data to define 
the role of thrombus consistency in RCC with VTT involving the IVC. Survival analysis 
showed no difference in survival between friable and solid thrombus consistency. 
Furthermore thrombus consistency was not of significance in prediction of survival. 
Traditionally used prognostic markers such as perinephric fat invasion, thrombus level or 
Fuhrman grade were shown to be of much stronger relevance. Our data confirmed once more 
metastatic disease as strongest independent predictor of poor survival. At present prognostic 
nomograms and models integrating clinical, pathological and molecular variables 
increasingly aim to guide cancer treatment. In RCC with VTT and IVC involvement the 
variable thrombus consistency failed to predict CSS and should therefore not be introduced 
in risk stratification models.
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Kaplan-Meier estimates of Cancer specific survival probability in patients with RCC and 
VTT involving the IVC [n = 413] stratified by thrombus consistency. Censored events are 
vertically marked. Log rank test showed no significant difference in survival probability 
between friable [n = 188] and solid [n = 255] VTT (p = 0.79).
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Table 1
Characteristics of RCC patients with IVC TT of RCC (at least pT3b stage) and 
descriptive statistics
All patients Friable IVC TT Solid IVC TT p value
no. of patients 413 188 225
pT stage p = 0.9a
pT3b 251 112 139
pT3c 130 61 69
pT4 32 15 17
Fuhrmann grade p=0.2b
1 9 4 5
2 96 39 57
3 194 83 111
4 114 62 52
VTT level (Mayo classification) p = 0.03a
1 113 48 65
2 136 75 61
3 85 37 48
4 79 28 51
Histological subtype p = 0.4a
Clear cell RCC 371 169 202
Papillary RCC 29 11 18
Chromophobe RCC 13 8 5
Nodal status p = 0.8a
N0 / Nx 297 134 163
N+ 116 54 62
Distant metastasis p = 0.2a
M0 / Mx 303 145 158
M1 110 43 67
Perinephric fat invasion p = 0.5a
Yes 266 124 142
No 147 64 83
IVC wall invasion P = 0.2 a
Yes 119 60 59
No 294 128 166
Sex p = 0.5a
Male 278 123 155
Female 135 65 70
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All patients Friable IVC TT Solid IVC TT p value
Age p = 0.49c
Mean 61,5 61,0 61,9
Median 62 61 63
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Table 2
Clinical features and cancer specific survival. Kaplan-Meier estimates and d Peto-Pike's log rank test.
Variable No. of patients Actuarial 5-yr CSS (%) Median CSS (months) p valued
Thrombus consistency p = 0.8
Friable 188 43,86 45
Solid 225 49,55 50
pT stage p < 0.001
pT3b 251 55,85 113
pT3c 130 39,51 35
pT4 32 11,36 17
Fuhrmann grade p < 0.001
1 9 25,4 26
2 96 71,35 >118
3 194 44,67 51
4 114 29,97 25
VTT level p < 0.001
1 113 67,91 >118
2 136 48,94 51
3 85 34,72 31
4 79 32,2 30
Histological subtype p = 0.005
cRCC 371 49,58 53
pRCC 29 26,48 20
chRCC 13 38,1 49
Nodal status p < 0.001
N0 / Nx 297 55,15 84
N+ 116 26,18 21
Distant metastasis p < 0.001
M0 / Mx 303 56,55 99
M1 110 19,84 15
Perinephric fat invasion p < 0.001
Yes 266 36,71 34
No 147 67,64 118
IVC wall invasion p < 0.01
Yes 119 31,42 32
No 294 51,72 81
Sex p = 0.2
Male 278 50,03 78
Female 135 42,56 41
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Variable No. of patients Actuarial 5-yr CSS (%) Median CSS (months) p valued
Age p = 0.1
<60 170 41,54 43
≥60 243 52,19 81
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